Co-Diagnostics (CODX) Stock Price, News & Analysis

Company Overview

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Key Stats

• Today's Range: $0.25 to $0.26
• 50-Day Range: $0.25 to $0.30
• 52-Week Range: $0.23 to $2.23
• Volume: 430,139 shs
• Average Volume: 850,541 shs
• Market Capitalization: $8.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Buy

Co-Diagnostics Stock Analysis - MarketRank™

Co-Diagnostics scored higher than 76% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Co-Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Co-Diagnostics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Co-Diagnostics are expected to grow in the coming year, from ($1.22) to ($1.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Co-Diagnostics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Co-Diagnostics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Co-Diagnostics has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.51% of the outstanding shares of Co-Diagnostics have been sold short.

Short Interest Ratio / Days to Cover

Co-Diagnostics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Co-Diagnostics has recently increased by 197.81%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Co-Diagnostics does not currently pay a dividend.

Dividend Growth

Co-Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.10

Percentage of Shares Shorted

2.51% of the outstanding shares of Co-Diagnostics have been sold short.

Short Interest Ratio / Days to Cover

Co-Diagnostics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Co-Diagnostics has recently increased by 197.81%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Co-Diagnostics this week, compared to 1 article on an average week.

Search Interest

4 people have searched for CODX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Co-Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.40% of the stock of Co-Diagnostics is held by insiders.

Percentage Held by Institutions

Only 14.99% of the stock of Co-Diagnostics is held by institutions.

CODX Stock Analysis - Frequently Asked Questions

How have CODX shares performed this year?

Co-Diagnostics' stock was trading at $0.75 at the beginning of 2025. Since then, CODX stock has decreased by 66.1% and is now trading at $0.2543.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.09. The business had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.38 million. Co-Diagnostics had a negative trailing twelve-month return on equity of 60.16% and a negative net margin of 1,025.45%.
Read the conference call transcript.

When did Co-Diagnostics IPO?

Co-Diagnostics (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

How do I buy shares of Co-Diagnostics?

Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 8/10/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CODX
• CIK: 1692415
• Web: www.codiagnostics.com
• Phone: (801) 438-1036
• Fax: N/A
• Employees: 100
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Co-Diagnostics: $5.50
• High Price Target: $10.00
• Low Price Target: $1.00
• Potential Upside/Downside: +2,062.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.64 million
• Net Margins: -1,025.45%
• Pretax Margin: -1,024.14%
• Return on Equity: -60.16%
• Return on Assets: -52.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.43
• Quick Ratio: 4.23

Sales & Book Value

• Annual Sales: $3.91 million
• Price / Sales: 2.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.70 per share
• Price / Book: 0.15

Miscellaneous

• Outstanding Shares: 33,570,000
• Free Float: 30,753,000
• Market Cap: $8.54 million
• Optionable: Optionable
• Beta: 0.51